TSH suppression therapy after total resection of thyroid cancer There is no consistent opinion on the therapeutic target of TSH, which requires comprehensive assessment of individual patient’s condition to set individualized target, and the overall range is generally below 2.0 mU/L. TSH inhibition therapy after total resection of thyroid cancer is mainly used to reduce the recurrence and metastasis rate, and oral preparations such as levothyroxine sodium tablets are generally preferred. However, there is no consistent opinion on the optimal target value of the therapy, and it is generally necessary to take into account the high or low risk of recurrence of the tumor of the patient, and the high or low risk of the occurrence of adverse effects of TSH inhibition therapy, and so on, to set up the corresponding therapeutic goals. For example, for patients with low risk of adverse reaction to TSH inhibition, if the risk of tumor recurrence one year after surgery is in the high risk group, the TSH inhibition target is recommended to be less than 0.1 mU/L, and one year later it is recommended to be controlled at 0.1~0.5 mU/L; while if the risk of tumor recurrence one year after surgery is in the low risk group, the TSH inhibition target is recommended to be in the range of 0.5~1.0 mU/L, and one year later it is recommended to be controlled at 1.0~2.5 mU/L. controlled at 1.0~2.0mU/L. The drug dosage of TSH suppression therapy after total resection of thyroid cancer as well as the TSH suppression target should follow the medical prescription, follow the physician’s advice, and review regularly to control the disease progression and prolong the life span as much as possible.